Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Eileen is awarded funding for her research into the tumour microenvironment

A picture of Eileen Parkes next to the Wellcome Trust logo

Dr Eileen Parkes has received a Wellcome Trust Clinical Research Career Development Fellowship. This prestigious and highly competitive award will support Eileen and her team with their research into the tumour microenvironment of highly chromosomally unstable oesophageal adenocarcinomas. These aggressive cancers have constitutive cGAS activation, and Eileen, her team and collaborators will model this using novel cell lines and organoids (including fibroblast and immune-cell co-cultures) to understand how this signalling axis impacts the formation of extracellular matrix and subsequent immune infiltration. By unpicking this mechanism, it is hoped that new anti-cancer targets will be identified.

 

I’m really excited about this work – there is an urgent need to improve how we treat oesophageal cancer, and this work will improve our understanding of the underlying mechanisms driving treatment resistance and disease progression, and hopefully identify new drug targets we can use against this aggressive disease .

- Eileen Parkes 

 You can read more about the Wellcome Trust and their mission here (opens in the new window).

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.